{"entity":{"id":"nct07110103","kind":"trial","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","aka":["JACKPOT38"],"tldr":"A phase 2 trial of golidocitinib in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","summary":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC is a phase 2, interventional study registered as NCT07110103 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 20 participants, started 2025-10-31 and due to reach its primary completion in 2027-03-31. Interventions recorded: golidocitinib with PD-1 inhibitors. Conditions listed: SCLC; SCLC, Extensive Stage. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed ES-SCLC (stage IV \\[any T stage, any N stage, M1 a/b/c stage\\] according to the 8th edition of the AJCC TNM staging system for lung cancer, or T3-4 stage disease caused by multiple lung nodules and the disease is too diffuse, or the tumor/nodule volume is to\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07110103","url":"https://clinicaltrials.gov/study/NCT07110103"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["golidocitinib"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07110103","phase":"2","setting":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment in Patients With Previously Untreated Extensive-stage Small Cell Lung Cancer: an Open-label, Single-arm, Phase 2 Study","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07110103/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"drug":[{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}